TBRA thinks phase-2 CENTAUR study could lead to an application for FDA accelerated approval in NASH based on 1-year data: https://www.clinicaltrials.gov/ct2/show/NCT02217475 1-year data for primary endpoint is expected in Jun 2014, according to the above listing.